Generex Biotechnology Short Interest Ratio and Short Volume

Generex Biotechnology (OTCMKTS:GNBT) Short Interest Frequently Asked Questions

What is Generex Biotechnology's current short interest?

Short interest is the volume of Generex Biotechnology shares that have been sold short but have not yet been closed out or covered. As of November 15th, traders have sold 60,600 shares of GNBT short. Learn More on Generex Biotechnology's current short interest.

Is Generex Biotechnology's short interest increasing or decreasing?

Generex Biotechnology saw a increase in short interest in November. As of November 15th, there was short interest totaling 60,600 shares, an increase of 551.6% from the previous total of 9,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Generex Biotechnology's short interest compare to its competitors?

0.00% of Generex Biotechnology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Generex Biotechnology: Synthetic Biologics, Inc. (0.16%), CohBar, Inc. (0.00%), Cellectar Biosciences, Inc. (0.00%), Unicycive Therapeutics, Inc. (0.80%), Exicure, Inc. (3.04%), Yumanity Therapeutics, Inc. (2.33%), Addex Therapeutics Ltd (0.00%), Rockwell Medical, Inc. (3.59%), Forte Biosciences, Inc. (5.85%), and Acerus Pharmaceuticals Co. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Generex Biotechnology stock?

Short selling GNBT is an investing strategy that aims to generate trading profit from Generex Biotechnology as its price is falling. Generex Biotechnology's stock is trading up $0.01 today. To short Generex Biotechnology stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Generex Biotechnology will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Generex Biotechnology?

A short squeeze for Generex Biotechnology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GNBT, which in turn drives the price of the stock up even further.

How often is Generex Biotechnology's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNBT, twice per month. The most recent reporting period available is November, 15 2021.